Benjamin Solomon

Research interests

Publications

• Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2024 · https://doi.org/10.1056/nejmoa2310532

• FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy

  Nature · 2024 · https://doi.org/10.1038/s41586-024-07242-1

• Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · 10.1016/j.annonc.2022.12.013

• Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

  The Lancet · 2023 · 10.1016/s0140-6736(23)00221-0

• Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2023 · 10.1016/j.annonc.2022.12.009

• Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

  Journal of Thoracic Oncology · 2022 · https://doi.org/10.1016/j.jtho.2022.10.003

• Lung cancer

  The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00312-3

• First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2027187

• Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group

  npj Breast Cancer · 2020 · https://doi.org/10.1038/s41523-020-0154-2

• Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005653

• Efficacy of Selpercatinib in RET -Altered Thyroid Cancers

  New England Journal of Medicine · 2020 · https://doi.org/10.1056/nejmoa2005651

• Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001

  Annals of Oncology · 2019 · https://doi.org/10.1093/annonc/mdz131

• Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30649-1

• Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology

  Archives of Pathology & Laboratory Medicine · 2018 · 10.5858/arpa.2017-0388-cp

• Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000162

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourina

  Advances in Anatomic Pathology · 2017 · https://doi.org/10.1097/pap.0000000000000161

• Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors

  Advances in Anatomic Pathology · 2017 · 10.1097/pap.0000000000000161

• Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(15)00614-2

• Comprehensive genomic profiles of small cell lung cancer

  Nature · 2015 · https://doi.org/10.1038/nature14664

• Ceritinib in ALK -Rearranged Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1311107

• First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1408440

• Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1214886

• Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer

  Nature Genetics · 2012 · 10.1038/ng.2396

• Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer

  Science Translational Medicine · 2010 · https://doi.org/10.1126/scitranslmed.3001451

• Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

  New England Journal of Medicine · 2010 · https://doi.org/10.1056/nejmoa1006448

Current projects

No projects listed.